Russell Investments Group’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,000
| Closed | -$39.3K | – | 4240 |
|
|
2025
Q4 | $39.3K | Sell |
3,000
-540
| -15% | -$6.45K | ﹤0.01% | 3387 |
|
|
2025
Q3 | $25.8K | Buy |
3,540
+3,506
| +10,312% | +$23.7K | ﹤0.01% | 3518 |
|
|
2025
Q2 | $182 | Hold |
34
| – | – | ﹤0.01% | 3794 |
|
|
2025
Q1 | $182 | Sell |
34
-351
| -91% | -$2.46K | ﹤0.01% | 3735 |
|
|
2024
Q4 | $3.44K | Hold |
385
| – | – | ﹤0.01% | 3354 |
|
|
2024
Q3 | $4.24K | Buy |
+385
| New | +$4.28K | ﹤0.01% | 3256 |
|
|
2024
Q2 | – | Sell |
-396
| Closed | -$5.57K | – | 3580 |
|
|
2024
Q1 | $5.57K | Buy |
+396
| New | +$4.93K | ﹤0.01% | 2924 |
|
|
2020
Q4 | – | Sell |
-4,008
| Closed | -$148K | – | 3040 |
|
|
2020
Q3 | $148K | Buy |
+4,008
| New | +$159K | ﹤0.01% | 2887 |
|
|
2018
Q4 | – | Sell |
-390
| Closed | -$19K | – | 2916 |
|
|
2018
Q3 | $19K | Buy |
+390
| New | +$17.5K | ﹤0.01% | 2911 |
|
Russell Investments Group's ATXS Position: Q1 2026 in Review
Russell Investments Group sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 3,000 shares — an estimated $39.3K sold.
Russell Investments Group first reported a position in ATXS in Q3 2018 and held it in 9 quarters. The position peaked at $148K in Q3 2020. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Russell Investments Group reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Russell Investments Group sold 3,000 Astria Therapeutics shares in Q1 2026, an estimated $39.3K.
- Russell Investments Group first reported a position in Astria Therapeutics in Q3 2018 and held it in 9 quarters.
- Russell Investments Group's Astria Therapeutics position peaked at $148K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.